Lantheus Holdings, Inc. , an established lcompany engaged in providing imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, recently announced that both the National Comprehensive Cancer Network (NCCN) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) have now updated their guidelines for the use of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging. Both the NCCN guidelines and the SNMMI appropriate use criteria note that all approved PSMA PET imaging agents, including PYLARIFY® (piflufolastat F 18), may be used for patient selection for PSMA-targeted radioligand therapy.

To read more please visit:

Lantheus Announces Updates to the NCCN Guidelines for PSMA PET Imaging for Prostate Cancer

Source: Lantheus